What is Crystagen 20MG

Crystagen 20MG is a short bioregulator tripeptide of the Khavinson family studied in research for its potent immunomodulatory action and targeted effects on the immune system. It is intended exclusively for research use.

Regarding its chemical identity, Crystagen has a molecular formula of C14H23N3O8 and a molecular weight of 361.3 g/mol. Its reported canonical sequence is Glu-Asp-Pro. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Crystagen.

Product for research use.

Mechanism of action of Crystagen

Crystagen regulates gene expression within cells of the immune system. It has been shown to normalize the ratio of T and B lymphocytes, enhance phagocytosis, and stabilize the production of pro-inflammatory and anti-inflammatory cytokines during immune stress.

Pharmacokinetics and pharmacodynamics of Crystagen

The peptide has an extremely brief half-life in biological fluids, functioning primarily as a rapid genetic trigger that sets off a prolonged cascade of immune normalization without requiring sustained circulating levels.

Scientific evidence on Crystagen

The available evidence on Crystagen is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Studied heavily in models of immunodeficiency, chronic infections, and post-operative immune suppression. It has demonstrated the capacity to accelerate the recovery of immune cell counts and function in animals subjected to radiation or severe stress.

Crystagen applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Crystagen protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Crystagen, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Crystagen

As a general guideline for laboratory handling, lyophilized peptides such as Crystagen are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Crystagen Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Crystagen security profile

The documented safety information in open sources for Crystagen is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Modulation of the immune system carries theoretical risks of either immune suppression or autoimmune over-activation. However, literature describes Crystagen primarily as a normalizer (bioregulator) rather than a strict stimulator.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Crystagen in a comparative context

Crystagen is the synthetic counterpart to the natural thymus extract Vladonix. Unlike Thymosin Alpha-1 which is a longer peptide that directly stimulates specific immune pathways, Crystagen acts at the epigenetic level to restore general immune homeostasis.

History and development of Crystagen

Developed by the Saint Petersburg Institute of Bioregulation and Gerontology. It was synthesized based on the analysis of amino acids found in thymus gland extracts to provide a highly purified, stable molecule for researching immune aging.